Canada — Health Canada & Optimi Health
8 shared events · Importance 3 · Last updated Sep 23, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
Canada — Health Canada: Canada — Health Canada's regulation of ibogaine under the Food and Drugs Act and its listing on the Prescription Drug List provides a favorable regulatory environment for Optimi Health's operations.
Optimi Health: Optimi Health has secured ibogaine supply and is commencing development of finished drug products, positioning itself as a key supplier in the emerging psychedelic therapy market.
Jun 08, 2026 · 14 articles
Tech
Canada — Health Canada: Canada — Health Canada authorized the clinical trial, enabling Optimi to proceed with the study. Its regulatory oversight is critical for the trial's legitimacy and future market authorization.
Optimi Health: Optimi Health is the central entity initiating the Phase 2 trial, which represents its largest clinical commitment to date and a strategic step toward potential drug registration. The trial could enhance its pipeline and market positioning, though it carries development risks and no near-term revenue.
Sep 10, 2026 · 15 articles
Business
Canada — Health Canada: Canada — Health Canada issued the Drug Establishment Licence (DEL) to Optimi Health, authorizing the company's manufacturing, packaging, labeling, testing, storage, and distribution of controlled drug products.
Optimi Health: Optimi Health completed its first export of psilocybin to the United Kingdom for a Phase 2 clinical trial, expanding its international market reach and solidifying its position as a vertically integrated GMP supplier of psychedelic drug products. It also completed a GMP production run of 5mg psilocybin capsules, with some earmarked for clinical research in the United States and Europe.
Jun 02, 2026 · 25 articles
Business
Canada — Health Canada: The regulator authorized prior trials led by Dr. Blough and will interact with Optimi on future trial applications and oversight.
Optimi Health: The company made the appointment to strengthen its clinical development capabilities ahead of planned Phase 2 psilocybin and Phase 3 MDMA trials. The move supports its pipeline but has limited near-term financial impact.
Sep 22, 2026 · 7 articles
Tech
Canada — Health Canada: Canada — Health Canada has issued a Drug Establishment License (DEL) to Optimi Health Corp., allowing it to produce and distribute regulated psychedelic drug products.
Optimi Health: Optimi Health Corp. has launched new microdose psilocybin products, expanding its product range and market reach for clinical research and therapeutic programs internationally. This development is expected to positively impact the company's revenue and market position.
Jun 16, 2026 · 11 articles
Business
Canada — Health Canada: Canada — Health Canada issued the Drug Establishment Licence for Optimi Health's facility and the export authorization for the psilocybin shipment to Australia, regulating the production and export of these controlled substances.
Optimi Health: Optimi Health completed its third commercial shipment of psilocybin to Australia, expanding its market presence and generating recurring revenue from the sale of its psychedelic drug products for medical use.
Jun 29, 2026 · 12 articles
Business
Canada — Health Canada: Canada — Health Canada is referenced as the licensing authority under which Optimi Health manufactures GMP-grade psychedelic drug products; no new regulatory action is involved in this event.
Optimi Health: Optimi Health is the central entity of the event, announcing its participation in the H.C. Wainwright 28th Annual Global Investment Conference and making its presentation available on demand from September 11, 2026. The event offers the company a platform to engage investors, though no financial or clinical news was disclosed.
Sep 08, 2026 · 6 articles
Business
Optimi Health: Optimi Health completed the first 2026 production and export of MDMA and psilocybin capsules to Australia, expanding its market access for psychedelic treatments for PTSD and TRD.
Jan 26, 2026 · 6 articles
70
Canada — Health Canada authorized clinical trial Optimi HealthOptimi Health Phase 2...
70
Canada — Health Canada authorized Phase 2 trial Optimi HealthOptimi Health Phase 2...
ERGEN INTELLIGENCE
Explore this relationship live
Track how Canada — Health Canada and Optimi Health interact across events, view sentiment trends, and discover connected entities.
Open Dashboard